MAPT and Alzheimer disease: While structural MRI results have limited security and specificity, a number of in vivo studies using functional MRI [187] and amyloid and tau PET (e.g., PiB, florbetabin, flutemetamole, etc.)[188]-[190] will enable the identification of AD and CVD patients in clinical and research settings.